AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

Key Concepts

• Pharmaceutical Manufacturing and R&D Investment: AstraZeneca's significant financial commitments to building and expanding manufacturing and research facilities in the United States.
• US Investment Commitments: AstraZeneca's pledge of $50 billion in US production and R&D by 2030, with specific investments in Maryland.
• Job Creation: The anticipated creation of approximately 2600 jobs through AstraZeneca's construction and expansion projects.
• Oncology Portfolio: AstraZeneca's strong focus and success in developing treatments for various types of cancer, particularly breast cancer.
• Drug Development Risk and Cost: The substantial financial risk and investment required for pharmaceutical research and development, with high failure rates.
• Most Favored Nation (MFN) Agreement/Equalization: A policy aimed at reducing drug costs for US patients by rebalancing prices with those in other wealthy countries.
• Biopharmaceutical Innovation: The importance of maintaining the US's leading position in global biopharmaceutical innovation.
• NYSE Listing: AstraZeneca's planned change in listing status to the New York Stock Exchange to increase visibility and accessibility for US investors.
• Diversified Disease Area Investment: AstraZeneca's investment beyond oncology into other areas like cardio-metabolism.

AstraZeneca's US Investment and Expansion

AstraZeneca, an Anglo-Swedish pharmaceutical giant, is making substantial investments in the United States, driven in part by President Trump's stance on pharmaceutical import tariffs. The company has committed to spending $50 billion on US production and R&D by 2030.

Maryland Expansion and New Facility

As part of this commitment, AstraZeneca unveiled a $2 billion investment in Maryland. This investment includes:

• Expansion of an existing biologics manufacturing facility.
• Construction of a new, state-of-the-art facility for the development and supply of new molecules intended for clinical trials.

Sir Pascal Soriot, CEO of AstraZeneca, confirmed that the $2 billion investment is being made in Frederick, Maryland, where a new biologics manufacturing site is being built. A second portion of the investment will fund a new clinical manufacturing unit in Gaithersburg, Maryland.

Job Creation

The construction and expansion projects are expected to create approximately 2600 jobs over the next five years, encompassing highly skilled scientists, technicians, engineers, factory workers, and construction personnel.

Broader Investment Strategy

This Maryland investment is the fourth announcement in six months, following commitments in Virginia and Coppell, Texas. It is part of AstraZeneca's overarching $50 billion commitment to invest in the US over the next five years in R&D and manufacturing.

AstraZeneca's Oncology Portfolio and Drug Development

AstraZeneca has a strong and growing portfolio in oncology, particularly in breast cancer.

Breast Cancer Treatment Advancements

• Enhertu: New data presented at ESMO (European Society of Medical Oncology) showed significant results for Enhertu in HER2-positive and HER2-low breast cancer, which affects a substantial proportion of patients. The data demonstrated benefits in early treatment.
• Triple-Negative Breast Cancer: AstraZeneca also announced results for a treatment for triple-negative breast cancer, a particularly aggressive disease with limited effective treatment options. The company demonstrated an overall survival benefit for patients.
• Clinical Development: AstraZeneca continues to build its pipeline with products in clinical development, aiming to make a significant impact in breast cancer treatment in the coming years.

Risk and Cost of Drug Development

Sir Pascal Soriot highlighted the immense cost and risk associated with pharmaceutical development. He stated that the team reviews new projects twice a month and that he frequently signs checks for hundreds of millions of dollars for new programs. For example, he recently signed for two Phase III studies in breast cancer, totaling $1 billion, with the risk of that investment being lost if the program fails. Despite these risks, AstraZeneca has achieved a success rate of about 80-90% in the last year or two, which has been appreciated by shareholders. This contrasts with many other drug companies that experience failure rates of up to 80%.

Most Favored Nation (MFN) Agreement and its Impact

AstraZeneca has reached an agreement with President Trump regarding drug pricing, which is described as a "Most Favored Nation" or "equalization/rebalancing" policy.

President's Goals

According to Sir Pascal Soriot, the President had two primary goals:

1. Reduce the cost of medicines for American patients.
2. Not destroy the biopharmaceutical industry, which is crucial for US global leadership in innovation.

The "Equalization" or "Rebalancing" Strategy

The challenge was to lower prices without harming the industry. The solution, termed "equalization" or "rebalancing," aims to allow US patients to pay less by having patients in other wealthy countries pay more. This addresses a price disconnect that has developed over the last 15 years, primarily between the US and Europe.

Benefits for Shareholders

While this policy may cause some short-term financial pain, AstraZeneca believes it can absorb it. The agreement provides visibility and certainty, allowing the company to refocus on innovation. Shareholders have appreciated this approach, as evidenced by AstraZeneca's stock price increase of 15% over the past year.

NYSE Listing and Future Growth

AstraZeneca is planning to change its listing status to the New York Stock Exchange (NYSE) in February.

Strategic Rationale for NYSE Listing

• US Market Focus: AstraZeneca considers itself a US company, with 25,000 employees in the US, two large R&D centers, and 16 manufacturing sites (with more planned). Their $50 billion investment commitment further solidifies this.
• Investor Accessibility: The goal is to make it easier for American investors, both large and small, to buy AstraZeneca shares. While American Depositary Receipts (ADRs) are an option, they are not always convenient for all investors.
• Visibility and Growth: Listing on the NYSE is expected to increase visibility and allow US shareholders to benefit from the company's future growth.

Diversified Investment Areas

AstraZeneca's growth strategy extends beyond oncology. They are also investing in:

• Cardio-metabolism: The company recently received "fantastic" Phase III results for a new drug for hypertension in patients whose condition is not controlled by three existing medications.
• Other Disease Areas: The company is investing across a variety of disease areas.

Revenue Target

AstraZeneca has a goal to achieve $80 billion in revenue by 2030, with 50% of that revenue originating from the United States.

Conclusion

AstraZeneca is demonstrating a significant commitment to the US through substantial investments in manufacturing and R&D, creating jobs, and advancing critical medical treatments, particularly in oncology. The company's strategic approach to drug development, coupled with its engagement in pricing policies like the MFN agreement, aims to balance patient affordability with industry innovation. The upcoming NYSE listing is expected to further enhance its presence and accessibility for US investors, supporting its ambitious growth targets across diverse therapeutic areas.